Drug Profile
OATD 01
Alternative Names: GLP 4716; GLPG-4716; OAT-889; OATD 01Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Yale University
- Developer Molecure
- Class Amines; Antiasthmatics; Antifibrotics; Chlorobenzenes; Hepatoprotectants; Morpholines; Nonsteroidal anti-inflammatories; Piperidines; Small molecules; Triazoles
- Mechanism of Action Acidic mammalian chitinase inhibitors; Chitotriosidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pulmonary sarcoidosis
- Phase I Interstitial lung diseases
- Research Fibrosis; Non-alcoholic steatohepatitis
- No development reported Asthma; Chronic obstructive pulmonary disease
- Discontinued Idiopathic pulmonary fibrosis
Most Recent Events
- 22 Mar 2024 Molecure plans to file an IND application with the EMA and Norwegian Medical Products Agency in European Union and Norway for Pulmonary sarcoidosis
- 04 Mar 2024 Phase-II clinical trials in Pulmonary sarcoidosis in United Kingdom, USA (PO) in March 2024 (NCT06205121)
- 29 Sep 2023 Molecure files an IND application with the MHRA in UK for Sarcoidosis